Nordicus Partners Corp · OTC:NORD
Nordicus Partners — Investor Presentation (January 2025)
21 slides from Nordicus Partners's investor presentation, Jan 2, 2025
Slide 1: Fostering the Next Generation of Nordic & U.S. Life Sciences Companies
NORDICUS FOSTERING THE NEXT GENERATION OF NORDIC & U.S. LIFE SCIENCES COMPANIES Investor Presentation Q1 2025 OTCQB: NORD | 1
Slide 2: Disclaimer
NORDICUS DISCLAIMER THIS MEMORANDUM MAY NOT BE READ, CIRCULATED, DISTRIBUTED, REPRODUCED, OR OTHERWISE USED FOR ANY PURPOSE OTHER THAN THE PURPOSE DESCRIBED HEREIN. WE DO NOT MAKE ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AS TO THE ACCURACY OR COMPLETENESS OF THE INFORMATION PROVIDED IN
Slide 3: The Nordicus Value Proposition
THE NORDICUS VALUE PROPOSITION Nordicus Partners is the only U.S. publicly traded business accelerator & holding company for Nordic life sciences companies. DUAL-MARKET EXPERTISE: © Leveraging Nordic innovation and U.S. operational know-how, to create a unique advantage in identifying, scaling and e
Slide 4: Nordicus Strategy: Transforming Potential into Value
NORDICUS ty NORDICUS STRATEGY: TRANSFORMING POTENTIAL INTO VALUE Q— si — wv — SCOUT ACCELERATE ACQUIRE EXIT a EXIT STRATEGIES AT PREMIUM MULTIPLES os AS Fe AS } IPO SALE OR PARTNERSHIP CONTINUE DRUG MERGER BIG PHARMA DEVELOPMENT OTCQB: NORD | 4 © Nordicus Partners Corporation - Al Rights Reserved
Slide 5: Scouting Criteria
NORDICUS SCOUTING CRITERIA = Target companies must be fully funded through Phase I. = Markets with no current medical treatments available today. = Addresses a significant unmet medical need in potential multibillion-dollar markets. © Nordicus Partners Corporation - Al Rights Reserved
Slide 6: Portfolio Company: Orocidin
th PORTFOLIO COMPANY: OROCIDIN Nordicus acquired 95% of Orocidin in May 2024 through an all-stock transaction, issuing 3,800,000 shares of its common stock, and completed the acquisition of the remaining 5% in November 2024 by issuing an additional 200,000 shares. OROCIDIN: A BREAKTHROUGH IN AGGRESS
Slide 7: Portfolio Company: Bio-Convert
NORDICUS PORTFOLIO COMPANY: BIO-CONVERT Nordicus acquired Bio-Convert in November 2024 through an all-stock transaction, issuing 12,000,000 shares of Nordicus' common stock. BIO-CONVERT: TRANSFORMING ORAL LEUKOPLAKIA (OLK) TREATMENT © Innovative Therapeutic: QR-02 is a proprietary oral formulation d
Slide 8: The Global Opportunity in Periodontal Disease
NORDICUS ty THE GLOBAL OPPORTUNITY IN PERIODONTAL DISEASE PERIODONTAL DISEASE: A GROWING GLOBAL CONCERN Global Prevalence Affects 20-50% of the global population (6° most prevalent health condition Severe periodontitis affects 11% globally U.S. Prevalence 42% of people aged 30+ are affected by perio
Slide 9: The Global Opportunity in Oral Cancer
NORDICUS THE GLOBAL OPPORTUNITY IN ORAL CANCER ORAL LEUKOPLAKIA (OLK) & ORAL CANCER: HIGH URGENCY, HIGH GROWTH Global Prevalence OLK affects approx. 2-4% of the global population 10-23% of OLK cases progress to oral cancer Market Size $274 billion $2.74 billion Oncology Drugs Oral Cancer Treatment C
Slide 10: Pipeline: Building the Future of Healthcare
PIPELINE: BUILDING THE FUTURE OF HEALTHCARE EVALUATING CNS DISORDERS: HIGH-IMPACT OPPORTUNITIES ° Obsessive-Compulsive Disorder (OCD): Focused on partial responders to existing treatments, addressing a gap in effective long-term solutions. Psychotic Depression: Developing therapies for a critical me
Slide 11: Why Invest?
NORDICUS WHY INVEST? o Portfolio Diversification Strategy: Nordicus’ balanced portfolio positions us as a stable and resilient company, mitigating risk with significant upside potential. o High-Growth Focus: Targeting life sciences markets with significant unmet medical needs. o Business Strategy: A
Slide 12: Cap Table
CAP TABLE MARKET CAP. SHARES OUTSTANDING WARRANTS OPTIONS FULLY DILUTED 52 WEEK HIGH / LOW © Nordicus Partners Corporation - Al Rights Reserved NORDICUS As of December 26, 2024 $159,080,224 17,197,862 575,300 450,000 18,223,162 $10.00 / $2.76 OTCQB: NORD | 12
Slide 13: Meet the Team
iy MEET THE TEAM Henrik Rouf (USA) Chief Executive Officer Mr. Rouf has 30 years of Board of Directors experience in the global finance markets, working as an international financier, merchant banker and fund manager, respectively. Prior to joining NORDICUS Partners, as the company’s Chief Executive
Slide 14: Contact
NORDICUS in X 6 You can reach us at: Tel: +1 310 666 0750 ae al a Nn k Yo U | 280 S. Beverly Drive, Suite 505 Beverly Hills, CA 90212 Info@nordicuspartners.com Investor Relations Jonathan Paterson Harbor Access Investor Relations Jonathan.Paterson@ Harbor-Access.com Tel: +1 475 477 9401 OTCQB: NORD
Slide 15: Appendices
APPENDICES NORDICUS OTCQB: NORD | 15
Slide 16: Appendices — Orocidin Background
ty APPENDICES — OROCIDIN BACKGROUND Orocidin NORDICUS Background OROCIDIN’s mission is to develop the preferred treatment against aggressive periodontitis. OROCIDIN’s innovative therapeutic agent, QR-01, distinguishes itself through its unique ability to restore the unbalance in the inflammatory sys
Slide 17: Appendices — Economics & Prevalence of Periodontal Diseases
NORDICUS ty APPENDICIES — THE ECONOMICS & PREVALENCE OF PERIODONTAL DISEASES 25 20 15 E10 BS 2 é L t 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 Year Economic Loss of Periodontal World Economic Loss Because Diseases in 2018 (Billion USS) of Periodontitis Around 2018 Europe (a2 countries)
Slide 18: Appendices — How Orocidin's QR-01 Works
NORDICUS APPENDICIES — HOW OROCIDIN’S QR-01 WORKS Periodontitis, a type of gum disease, is severe inflammation of your gums, with symptoms that include red, bleeding or swollen gums. It’s also a bacterial infection that starts by inflaming the soft tissues around your teeth. Left untreated, it erode
Slide 19: Appendices — Bio-Convert Background
APPENDICES — BIO-CONVERT BACKGROUND Background Bio-Convert’s mission is to develop the preferred treatment for oral leukoplakia (“OLK’). Bio-Convert’s innovative therapeutic agent, QR-02, uses a novel proprietary oral formulation aimed at treating OLK and reduce the probability of OLK converting to
Slide 20: Appendices — Economics & Prevalence of OLK & Oral Cancer
NORDICUS ty APPENDICIES — THE ECONOMICS & PREVALENCE OF OLK & ORAL CANCER USD 274 Billion in 2030 Market Size Global Market For Oncology Drugs 7.5% CAGR from Prevalence of Oral Leukoplakia EU=8.9M 2021-2030 US-6.6M ~80% USD 2.74 Billion in 2030 Value of Oral Cancer Treatment of oral leukoplakia case
Slide 21: Oral leukoplakia (OLK) is a common oral potentially malignant disorder
Oral leukoplakia (“OLK”) is a common oral potentially malignant disorder, characterized by predominantly white painless patches/plaques being present in the oral cavity, either localized or in multiple areas. Oral potentially malignant disorders refer to those disorders that has the potential to tra
Nordicus Partners — Investor Presentation (January 2025) on 6ix